Pfizer Inc.
Have Watchlists? Log in to see them here or sign up to get started.
No Items in Watchlist
There are currently no items in this Watchlist.
No Saved Watchlists
Create a list of the investments you want to track.
Uh oh
Something went wrong while loading Watchlist.
Recently Viewed Tickers
No Recent Tickers
Visit a quote page and your recently viewed tickers will be displayed here.
Overview
PFE Overview
Key Data
Performance
Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Recent News
Pfizer Inc. stock underperforms Tuesday when compared to competitors despite daily gains
Barron’s Moderna Confirms Covax Turned Down More Covid-19 Vaccine Doses
Barron’s Novartis CEO Continues His Shake-Up, Says It Will Save More Than $1 Billion Annually
Pfizer Inc. stock falls Monday, underperforms market
Tesla is one of only 11 stocks in the S&P 500, excluding energy, that enjoys this critical support
Pfizer Inc. stock falls Friday, underperforms market
U.S. lawmakers close to agreeing on $10 billion in funding for next phase of the COVID-19 battle, as death toll tops 980,000
Biden says U.S. turning corner on COVID, but experts are worried that BA.2 is pushing cases higher in 15 states
Pfizer Inc. stock falls Thursday, still outperforms market
‘COVID-19 no longer controls our lives,’ Biden says, while rolling out website for living with virus
Pfizer Inc. stock underperforms Wednesday when compared to competitors
Barron’s BioNTech’s Earnings Top Estimates. It Plans a Buyback and Special Dividend.
BioNTech reports soaring earnings, revenue on COVID vaccine, plans $1.5 billion in buybacks
Barron’s The Bond Market Is Flashing a Recession Warning—but Stocks Have Thrived After Inversion
FDA approves another Pfizer, Moderna COVID booster for those 50 and older
U.S. FDA authorizes second COVID booster dose for people aged 50 and older
US FDA approves second COVID booster shot for people aged 50 and older
Barron’s FDA Authorizes Second Covid Booster for Adults Aged 50 and Up
Pfizer’s etrasimod hits goals again in ulcerative colitis study
Barron’s The BA.2 Covid Variant Is Already Changing the U.S. Response to the Pandemic
No Headlines Available
Pfizer’s $6.7 Billion Bet Could Be About to Pay Off Big Time
7 Safe Stocks to Buy to Guard Against a Recession
Why Pfizer Stock Popped on Tuesday
3 Vanguard ETFs to Buy Now
What This Regulatory Approval Could Mean for Merck
Annual Boosters Might Not Give Moderna the Boost It Needs
7 Biotech Stocks to Buy With Key Catalysts for April
Moderna’s Billion-Dollar mRNA Story Is Just Getting Started
How to Approach Trading Downtrodden Novavax Today
Pfizer Stock: Can Booster Season Boost Shares?
Buying Vaccine Stocks? Look at These 2 Charts First
3 Top Healthcare Stocks to Make Your Portfolio Smarter
Why Novavax Stock Dipped On Thursday
3 Vaccine Stocks to Buy on the New Covid Variant Surge
Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?
PFE Stock: What’s Going on With Pfizer This Week?
MRNA Stock: What’s Going on With Moderna This Week?
BioNTech News: Why Is BNTX Stock Up Today?
3 Charts You Have to See Before Buying Moderna
5 Charts That Show Why Bristol-Myers Squibb Is a No-Brainer Buy
No Headlines Available
Pfizer Inc.
Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Johnson & Johnson | 0.65% | $464.05B |
| Eli Lilly & Co. | 0.37% | $277.53B |
| Abbott Laboratories | 0.50% | $209.64B |
| Merck & Co. Inc. | 0.28% | $211.04B |
| Novartis AG | 0.43% | CHF181.78B |
| AstraZeneca PLC ADR | 0.00% | $206.1B |
| AstraZeneca PLC | 1.89% | £157.15B |
| Bristol Myers Squibb Co. | 0.87% | $156.82B |
| Amgen Inc. | -0.13% | $136.4B |
| Moderna Inc. | -6.08% | $69.54B |
Partner Content
Partner Content
Copyright © 2022 MarketWatch, Inc. All rights reserved.
MarketWatch
Company
Dow Jones Network
Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
